insights_auto
为什么 DMN 下跌了 5.11%?
深入探索chevron_right
DMN:FRA
Diamyd Medical AB
€0.059
arrow_downward
-5.11%(-0.0032) 1 天
11月20日, GMT+1 22:00:00 · EUR
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 DMN 生成关键数据洞见…
开盘价
€0.06
最高价
€0.06
最低价
€0.06
市值
1.35亿
平均成交量
0.00
成交量
0.00
52 周最高价
€1.80
52 周最低价
€0.05
员工人数
42
开盘价
€0.06
最高价
€0.06
最低价
€0.06
市值
1.35亿
平均成交量
0.00
成交量
0.00
52 周最高价
€1.80
52 周最低价
€0.05
员工人数
42
新闻报道
来自网络来源和新闻合作伙伴
24/7 Wall St.
·
1小时前
The S&P 500 Just Plunged 9% in a Week. Charlie Munger Once Lost 53% in Two Years. Here's His Test for a 66-Year-Old With $2 Million
Traders Union
·
2小时前
Seventeen of the twenty largest S&P 500 drops began below the 200-day moving average, Ryan Detrick notes
JournalArta
·
1小时前
S&P 500 Stocks Fall 8.6% in a Week as AI Shares Slide
资料
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
Diamyd Medical AB简介